High rates of tuberculin skin test positivity due to methotrexate therapy: False positive results?

Seminars in Arthritis and Rheumatism

Volumn 48, Issue 3, 2018, Pages 538-546

  Arias Guillén, Miguel ^a   Sánchez Menéndez, Marta M ^b   Alperi, Mercedes ^c   Riestra, Sabino ^c   González Budiño, María Teresa ^a   García Clemente, Marta María ^a   Martínez González, Susana ^a   Enríquez, Ana Isabel ^d   Alonso Arias, Rebeca ^c   Palacios Gutiérrez, Juan José ^c   Santibáñez, Miguel ^e   Coto Segura, Pablo ^c   Camblor, Pablo Martínez ^f,g   García Alfonso, Lucía ^a   Morante, Isla ^h   Escalante, Patricio ⁱ  

^a Instituto Nacional de Silicosis   (Spain)

^b Centro Medico de Asturias   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^d HOSPITAL SEVERO OCHOA   (Spain)

^e UNIVERSITY OF CANTABRIA   (Spain)

^f DARTMOUTH MEDICAL SCHOOL   (United States)

^g UNIVERSIDAD AUTÓNOMA DE CHILE   (Chile)

^h HOSPITAL SIERRALLANA   (Spain)

ⁱ MAYO CLINIC   (United States)

Author keywords

interferon ? release assays; latent tuberculosis infection; methotrexate; rheumatic disease; Tuberculin Skin Test

Indexed keywords

BIOLOGICAL PRODUCT; CORTICOSTEROID DERIVATIVE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; LEFLUNOMIDE; METHOTREXATE;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; FALSE POSITIVE RESULT; FEMALE; HUMAN; INTERFERON GAMMA RELEASE ASSAY; INTERMETHOD COMPARISON; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIATIC ARTHRITIS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SCREENING TEST; TUBERCULIN TEST; MIDDLE AGED;

ADULT; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; LATENT TUBERCULOSIS; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; RHEUMATIC DISEASES; TUBERCULIN TEST;

EID: 85046624272     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2018.03.018     Document Type: Article

References (27)

1. World Health Organization: Global Tuberculosis Report 2016. Geneva, Switzerland, 2016. http://apps.who.int/medicinedocs/documents/s23098en/s23098en.pdf.
2. Costantino, F., de Carvalho Bittencourt, M., Rat, A.C., et al. Screening for latent tuberculosis infection in patients with chronic inflammatory arthritis: discrepancies between tuberculin skin test and interferon-? release assay results. J Rheumatol 40 (2013), 1986–1993.
3. N\xFAñez Martínez, O., Ripoll Noiseux, C., Carneros Martin, J.A., et al. Reactivation tuberculosis in a patient with anti-TNF-alpha treatment. Am J Gastroenterol 96 (2001), 1665–1666.
4. Keane, J., Gershon, S., Wise, R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 (2001), 1098–1104.
5. Ford, A.C., Peyrin-Biroulet, L., Opportunistic infections with anti-tumor necrosis factor-a therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol 108 (2013), 1268–1276.
6. Bongartz, T., Sutton, A.J., Sweeting, M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. J Am Med Assoc, 2006, 2275–2285.
7. Solovic, I., Sester, M., Gomez-Reino, J.J., et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 36 (2010), 1185–1206.
8. Saukkonen, J.J., Cohn, D.L., Jasmer, R.M., et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 174 (2006), 935–952.
9. Gomez-Reino, J.J., Carmona, L., Valverde, V.R., et al., for the BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48 (2003), 2122–2127.
10. Mack, U., Migliori, G.B., Sester, M., et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 33 (2009), 956–973.
11. Arango Duque, G., Descoteaux, A., Macrophage cytokines: involvement in immunity and infectious diseases. Front Immunol, 5, 2014, 491.
12. Pai, M., Denkinger, C.M., Kik, S.V., et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev 27 (2014), 3–20.
13. Felson, D.T., Smolen, J.S., Wells, G., et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 63 (2011), 573–586.
14. Sztajnbok, F., Boechat, N.L., Ribeiro, S.B., et al. Tuberculin Skin Test and ELISPOT/T.SPOT.TB in children and adolescents with juvenile idiopathic arthritis. Pediatr Rheumatol Online J, 12, 2014, 17.
15. Brown, P.M., Pratt, A.G., Isaacs, J.D., Mechanisms of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat Rev Rheumatol 12 (2016), 731–742.
16. Steiman, A.J., Pope, J.E., Thiessen-Philbrook, H., et al. Non-biologic disease-modifying antirheumatic drugs (DMARDs) improve pain in inflammatory arthritis (IA): a systematic literature review of randomized controlled trials. Rheumatol Int 33 (2013), 1105–1120.
17. Bulatovic Calasan, M., Vastert, S.J., Scholman, R.C., et al. Methotrexate treatment affects effector but not regulatory T cells in juvenile idiopathic arthritis. Rheumatology (Oxford) 54 (2015), 1724–1734.
18. Sester, M., van Leth, F., Bruchfeld, J., et al. Risk assessment of tuberculosis in immunocompromised patients. A TBNET study. Am J Respir Crit Care Med 190 (2014), 1168–1176.
19. Wong, S.H., Gao, Q., Tsoi, K.K., et al. Effect of immunosuppressive therapy on interferon ? release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis. Thorax 71 (2016), 64–72.
20. Mir Viladrich, I., Daudén Tello, E., Solano-L\xF3pez, G., et al. Consensus document on prevention and treatment of tuberculosis in patients for biological treatment. Arch Bronconeumol 52 (2016), 36–45.
21. Arias-Guillén, M., Riestra, S., de Francisco, R., et al. T-cell profiling and the immunodiagnosis of latent tuberculosis infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 20 (2014), 329–338.
22. Luetkemeyer, A.F., Charlebois, E.D., Flores, L.L., et al. Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV infected individuals. Am J Respir Crit Care Med 175 (2007), 737–742.
23. Raby, E., Moyo, M., Devendra, A., et al. The effects of HIV on the sensitivity of a whole blood IFN-gamma release assay in Zambian adults with active tuberculosis. PLoS One, 3, 2008, e2489.
24. Farhat, M., Greenaway, C., Pai, M., et al. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria?. Int J Tuberc Lung Dis 10 (2006), 1192–1204.
25. Matulis, G., J\xFCni, P., Villiger, P.M., et al. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. Ann Rheum Dis 67 (2008), 84–90.
26. Brown, P.M., Pratt, A.G., Isaacs, J.D., Mechanisms of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat Rev Rheumatol 12 (2016), 731–742.
27. Agarwal, S., Das, S.K., Agarwal, G.G., et al. Steroids decrease prevalence of positive tuberculin skin test in rheumatoid arthritis: implications on anti-TNF therapies. Interdiscip Perspect Infect Dis, 2014, 2014, 10.1155/2014/430134.